¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.
ÀΰøÀå±â ¹× ¹ÙÀÌ¿À´Ð½º ½ÃÀå ¼ºÀå ¹× µ¿Çâ :
Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼¿¡ µû¸£¸é, ¼¼°è ÀΰøÀå±â ¹× ¹ÙÀÌ¿À´Ð½º ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 700¾ï 9,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¿¹Ãø ±â°£ µ¿¾È CAGR 9.3%·Î È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
Àå±â ºÎÀü À¯º´·ü Áõ°¡·Î ÀÎÇØ Àΰø Àå±â ¹× ¹ÙÀÌ¿À´Ð½º ÀåÄ¡ÀÇ »ç¿ëÀÌ Å©°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ½ÅÀå, ½ÉÀå, Æó, °£, ÃéÀåÀ» À̽ÄÇÏ´Â ±âÁõÀÚ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù. ¶ÇÇÑ, ¸¹Àº »ý¸í°øÇÐ ¹× ÀÇ·á±â±â ȸ»çµéÀÌ 3D ÇÁ¸°Å͸¦ ÀÌ¿ëÇÑ ¹ÙÀÌ¿À´Ð½º °³¹ß¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀåÄ¡´Â ±ÙÀüµµ ¹× °¨°¢ Àü±â ±â¼úÀ» »ç¿ëÇÏ¿© ÀÎüÀÇ Àΰø ºÎǰÀÇ À̵¿¼ºÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù.
Äڷγª19 ÆÒµ¥¹ÍÀº ÀΰøÀå±â ¹× ¹ÙÀÌ¿À´Ð½º ½ÃÀå¿¡ ºÎÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. ±â´É Àå¾Ö¿Í Àå±â ºÎÀüÀ» °¡Áø ȯÀÚµéÀº Àü¿°º´À¸·Î ÀÎÇØ ´õ ¸¹Àº ¹®Á¦¿¡ Á÷¸éÇß½À´Ï´Ù. »çȸÀû °Å¸®µÎ±â·Î ÀÎÇØ ¸¹Àº ÀÇ·á ½Ã¼³Àº ºñ¼±ÅÃÀû ½Ã¼ú°ú ¼ö¼ú¿¡ Á¦ÇÑÀ» ¹Þ¾Ò°í, ½ÃÀå ¼ºÀåÀÇ ÇѰ踦 ±Øº¹Çϱâ À§ÇØ Àå¾Ö°¡ Àִ ȯÀڵ鿡°Ô È»óȸÀǸ¦ Á¦°øÇß½À´Ï´Ù. ¶ÇÇÑ ½ÃÀå ¼ºÀåÀ» ¹æÇØÇÏ´Â Ä¡·áÀÇ ÇѰ赵 ÀÖ½À´Ï´Ù.
Á¦Ç° Ãâ½Ã Áõ°¡¿Í FDAÀÇ ½Å¼ÓÇÑ ½ÂÀÎÀ¸·Î ±âÁõÀÚ ºÎÁ·ÀÌ ÇØ¼ÒµÇ°í ÀÖ½À´Ï´Ù. Àΰø ÀÎü ºÎǰ¿¡ ´ëÇÑ ¿¬±¸ °³¹ß Áõ°¡´Â Àΰø Àå±â ¹× ¹ÙÀÌ¿À´Ð½º ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 3¿ù 31ÀÏ Edwards Lifesciences´Â ½ÉÀåÀÇ ½Â¸ðÆÇ¸· À§Ä¡¿¡ ¸Â°Ô ¼³°èµÈ MITRIS RESILIA ÆÇ¸·(Á¶Á÷Á¢ ÆÇ¸Å¸· ġȯ¼ú)ÀÌ FDAÀÇ ½ÂÀÎÀ» ¹Þ¾Ò´Ù°í ¹àÇû½À´Ï´Ù. ÀÌó·³ ÀÇ·áºñ ÁöÃâ Áõ°¡¿Í FDAÀÇ Àΰø ÀÎü ºÎǰ¿¡ ´ëÇÑ ½Å¼ÓÇÑ ½ÂÀÎÀ¸·Î ÀÎÇØ ½ÃÀåÀº ¿¹Ãø ±â°£ µ¿¾È °ß°íÇÑ ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÀΰøÀå±â ¹× ¹ÙÀÌ¿À´Ð½º ½ÃÀå º¸°í¼ ÇÏÀ̶óÀÌÆ®
- ÀΰøÀå±â ºÐ¾ß´Â ÀÌ½Ä ¼ö¼ú °Ç¼ö Áõ°¡·Î ÀÎÇØ 2022³â ´Ù¸¥ ¸ðµç ºÐ¾ß Áß °¡Àå ¸¹Àº ¼öÀÍÀ» âÃâÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¹ÙÀÌ¿À´Ð½º ºÐ¾ßµµ Á¦Ç° ¹ßÀüÀ¸·Î ÀÎÇØ °¡Àå ³ôÀº CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
- ½ÅÀå ºÐ¾ß´Â ½ÅºÎÀüÁõ Áõ°¡·Î ÀÎÇØ 2022³â ¾à 57.3%ÀÇ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
- Àΰø¿Í¿ì ºÐ¾ß´Â ³ë·ÉÀα¸ Áõ°¡·Î ÀÎÇØ °¡Àå ³ôÀº ¼ºÀå·üÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
- ºÏ¹Ì´Â 2022³â Áö¿ªº°·Î 1À§¸¦ Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, °í±Þ ÀÇ·á ½Ã¼³ÀÇ Á¸Àç·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È ±× ÁöÀ§¸¦ À¯ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå ÀΰøÀå±â ¹× ¹ÙÀÌ¿À´Ð½º ½ÃÀå º¯¼ö, µ¿Çâ ¹× ¹üÀ§
- ½ÃÀå °èÅë Àü¸Á
- »óÀ§ ½ÃÀå Àü¸Á
- °ü·Ã/ºÎ¼ö ½ÃÀå Àü¸Á
- º¸±Þ°ú ¼ºÀå Àü¸Á ¸ÅÇÎ
- ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
- ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
- ÀΰøÀå±â ¹× ¹ÙÀÌ¿À´Ð½º ½ÃÀå ºÐ¼® Åø
- ¾÷°è ºÐ¼® - PorterÀÇ Five Forces ºÐ¼®
- PESTEL ºÐ¼®
Á¦4Àå ÀΰøÀå±â ¹× ¹ÙÀÌ¿À´Ð½º : Á¦Ç°º° ÃßÁ¤¡¤µ¿Ç⠺м®
- ÀΰøÀå±â ¹× ¹ÙÀÌ¿À´Ð½º ½ÃÀå : Áß¿ä Æ÷ÀÎÆ®
- ÀΰøÀå±â ¹× ¹ÙÀÌ¿À´Ð½º ½ÃÀå : µ¿Çâ ¹× ½ÃÀå Á¡À¯À² ºÐ¼®, 2022³â ¹× 2030³â
- Àΰø Àå±â
- Àΰø Àå±â ½ÃÀå Ã߻ꡤ¿¹Ãø, 2018³â-2030³â
- ½ÅÀå
- ½ÉÀå
- °£
- Æó
- ̎ˌ
- Àΰø ¹ÙÀÌ¿À´Ð½º
- Àΰø ¹ÙÀÌ¿À´Ð½º ½ÃÀå Ã߻ꡤ¿¹Ãø, 2018³â-2030³â
- Àΰø¿Í¿ì
- ¿Ü°ñ°Ý
- Bionic limbs
- Vision limbs
- ºê·¹ÀÎ ¹ÙÀÌ¿À´Ð½º
Á¦5Àå ÀΰøÀå±â ¹× ¹ÙÀÌ¿À´Ð½º : ±â¼úº° ÃßÁ¤¡¤µ¿Ç⠺м®
- ÀΰøÀå±â ¹× ¹ÙÀÌ¿À´Ð½º ½ÃÀå : Áß¿ä Æ÷ÀÎÆ®
- ÀΰøÀå±â ¹× ¹ÙÀÌ¿À´Ð½º ½ÃÀå : µ¿Çâ ¹× ½ÃÀå Á¡À¯À² ºÐ¼®, 2022³â ¹× 2030³â
- ±â°è½Ä
- ÀüÀÚ
Á¦6Àå ÀΰøÀå±â ¹× ¹ÙÀÌ¿À´Ð½º ½ÃÀå : Áö¿ªº° ÃßÁ¤¡¤µ¿Ç⠺м®
- Áö¿ªº° Àü¸Á
- Áö¿ªº° ÀΰøÀå±â ¹× ¹ÙÀÌ¿À´Ð½º ½ÃÀå : Áß¿ä Æ÷ÀÎÆ®
- ºÏ¹Ì
- ½ÃÀå Ã߻ꡤ¿¹Ãø, 2018-2030³â
- ¹Ì±¹
- ij³ª´Ù
- À¯·´
- ¿µ±¹
- µ¶ÀÏ
- ÇÁ¶û½º
- ÀÌÅ»¸®¾Æ
- ½ºÆäÀÎ
- ½º¿þµ§
- ³ë¸£¿þÀÌ
- µ§¸¶Å©
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- ÀϺ»
- Áß±¹
- Àεµ
- È£ÁÖ
- ű¹
- Çѱ¹
- ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- »ç¿ìµð¾Æ¶óºñ¾Æ
- ³²¾ÆÇÁ¸®Ä«°øÈ±¹
- ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
- Äí¿þÀÌÆ®
Á¦7Àå °æÀï ±¸µµ
- ÁÖ¿ä ½ÃÀå ÁøÃâ±â¾÷ÀÇ ÃÖ±Ù µ¿Çâ°ú ¿µÇ⠺м®
- ½ÃÀå ÁøÃâ±â¾÷ ºÐ·ù
- ABIOMED
- Berlin Heart
- Zimmer Biomet
- Boston Scientific Corporation
- Cochlear Ltd.
- Edwards Lifesciences Corporation
- Ekso Bionics
- Medtronic
- Jarvik Heart, Inc
- SynCardia Systems, LLC
LSH 23.10.31
Artificial Organs And Bionics Market Growth & Trends:
The global artificial organs and bionics market size is expected to reach USD 70.09 billion by the year 2030, expanding at a compound annual growth rate (CAGR) of 9.3% during the forecast period, according to a new report by Grand View Research, Inc.. The increasing prevalence of organ failure has resulted in a massive increase in using human-made organs and bionics devices. The rising demand for donors to transplant kidneys, hearts, lungs, livers, and pancreas is a major factor boosting the market growth. Moreover, many biotechnology and medical device companies have concentrated on developing 3D printed bionic. These devices use myoelectric technology and sensory electric technology that enable the mobility of synthetic human body parts.
The COVID-19 pandemic had a detrimental effect on the artificial organ and bionics market. Patients with impairments and organ failures faced additional challenges due to the pandemic. Due to social distancing, many medical facilities were limited to non-elective procedures and surgeries and instead offered patients with impairments video conferencing to conquer market growth limitations. Moreover, there are treatment limitations that have hampered the growth of the market.
An increasing number of product launches and speedy FDA approval of these devices are bridging the shortage of donors. Rising R&D in synthetic human body parts is also boosting artificial organ and bionics market growth. For instance, on March 31, 2022, Edwards Lifesciences confirmed that the FDA certified the MITRIS RESILIA valve (a tissue valve replacement) that is specifically designed for the mitral position of the heart. Thus, with increasing healthcare expenditure and speedy FDA approval of synthetic human body parts, the market is expected to see robust growth during the forecast period.
Artificial Organs And Bionics Market Report Highlights:
- The artificial organs segment generated the most revenue among all other segments in 2022 due to an escalating number of transplant procedures. The bionics segment is also expected to witness the highest CAGR owing to advancements in products
- The kidney segment accounted for the largest market share of approximately 57.3% in the year 2022, owing to increasing kidney failures
- The cochlear implant segment is expected to register the highest growth rate owing to the increasing geriatric population
- North America was the leading regional segment in 2022 and is expected to maintain its position during the forecast period owing to the presence of advanced healthcare facilities
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Product
- 1.1.2. Technology
- 1.1.3. Regional scope
- 1.1.4. Estimates and forecast timeline
- 1.2. Research Methodology
- 1.3. Information Procurement
- 1.3.1. Purchased database
- 1.3.2. GVR's internal database
- 1.3.3. Secondary sources
- 1.3.4. Primary research
- 1.3.5. Details of primary research
- 1.4. Information or Data Analysis
- 1.5. Market Formulation & Validation
- 1.6. Model Details
- 1.7. List of Secondary Sources
- 1.8. List of Primary Sources
- 1.9. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Product outlook
- 2.2.2. Technology outlook
- 2.2.3. Regional outlook
- 2.3. Competitive Insights
Chapter 3. Artificial Organ and Bionics Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Penetration & Growth Prospect Mapping
- 3.3. Market Dynamics
- 3.3.1. Market driver analysis
- 3.3.2. Market restraint analysis
- 3.4. Artificial Organ and Bionics Market Analysis Tools
- 3.4.1. Industry Analysis - Porter's
- 3.4.1.1. Supplier power
- 3.4.1.2. Buyer power
- 3.4.1.3. Substitution threat
- 3.4.1.4. Threat of new entrant
- 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
- 3.4.2.1. Political landscape
- 3.4.2.2. Technological landscape
- 3.4.2.3. Economic landscape
Chapter 4. Artificial Organ and Bionics: Product Estimates & Trend Analysis
- 4.1. Artificial Organ and Bionics Market: Key Takeaways
- 4.2. Artificial Organ and Bionics Market: Movement & Market Share Analysis, 2022 & 2030
- 4.3. Artificial Organs
- 4.3.1. Artificial organs market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.3.2. Kidney
- 4.3.2.1. Kidney market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.3.3. Heart
- 4.3.3.1. Heart market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.3.4. Liver
- 4.3.4.1. Liver market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.3.5. Lungs
- 4.3.5.1. Lungs market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.3.6. Pancreas
- 4.3.6.1. Pancreas market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.4. Artificial Bionics
- 4.4.1. Artificial bionics market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.4.2. Cochlear implant
- 4.4.2.1. Cochlear implant market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.4.3. Exoskeleton
- 4.4.3.1. Exoskeleton market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.4.4. Bionic limbs
- 4.4.4.1. Bionic limbs market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.4.5. Vision limbs
- 4.4.5.1. Vision limbs market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.4.6. Brain bionics
- 4.4.6.1. Brain bionics market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Artificial Organ and Bionics: Technology Estimates & Trend Analysis
- 5.1. Artificial Organ and Bionics Market: Key Takeaways
- 5.2. Artificial Organ and Bionics Market: Movement & Market Share Analysis, 2022 & 2030
- 5.3. Mechanical
- 5.3.1. Mechanical market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4. Electronic
- 5.4.1. Electronic market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Artificial Organ and Bionics Market: Regional Estimates & Trend Analysis
- 6.1. Regional Outlook
- 6.2. Artificial Organ and Bionics Market by Region: Key Takeaways
- 6.3. North America
- 6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.3.2. U.S.
- 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.3.3. Canada
- 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4. Europe
- 6.4.1. UK
- 6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4.2. Germany
- 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4.3. France
- 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4.4. Italy
- 6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4.5. Spain
- 6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4.6. Sweden
- 6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4.7. Norway
- 6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4.8. Denmark
- 6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.5. Asia Pacific
- 6.5.1. Japan
- 6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.5.2. China
- 6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.5.3. India
- 6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.5.4. Australia
- 6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.5.5. Thailand
- 6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.5.6. South Korea
- 6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.6. Latin America
- 6.6.1. Brazil
- 6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.6.2. Mexico
- 6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.6.3. Argentina
- 6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.7. MEA
- 6.7.1. Saudi Arabia
- 6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.7.2. South Africa
- 6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.7.3. UAE
- 6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.7.4. Kuwait
- 6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
Chapter 7. Competitive Landscape
- 7.1. Recent Developments & Impact Analysis, By Key Market Participants
- 7.2. Market Participant Categorization
- 7.2.1. ABIOMED
- 7.2.1.1. Company overview
- 7.2.1.2. Financial performance
- 7.2.1.3. Product benchmarking
- 7.2.1.4. Strategic initiatives
- 7.2.2. Berlin Heart
- 7.2.2.1. Company overview
- 7.2.2.2. Financial performance
- 7.2.2.3. Product benchmarking
- 7.2.2.4. Strategic initiatives
- 7.2.3. Zimmer Biomet
- 7.2.3.1. Company overview
- 7.2.3.2. Financial performance
- 7.2.3.3. Product benchmarking
- 7.2.3.4. Strategic initiatives
- 7.2.4. Boston Scientific Corporation
- 7.2.4.1. Company overview
- 7.2.4.2. Financial performance
- 7.2.4.3. Product benchmarking
- 7.2.4.4. Strategic initiatives
- 7.2.5. Cochlear Ltd.
- 7.2.5.1. Company overview
- 7.2.5.2. Financial performance
- 7.2.5.3. Product benchmarking
- 7.2.5.4. Strategic initiatives
- 7.2.6. Edwards Lifesciences Corporation
- 7.2.6.1. Company overview
- 7.2.6.2. Financial performance
- 7.2.6.3. Product benchmarking
- 7.2.6.4. Strategic initiatives
- 7.2.7. Ekso Bionics
- 7.2.7.1. Company overview
- 7.2.7.2. Financial performance
- 7.2.7.3. Product benchmarking
- 7.2.7.4. Strategic initiatives
- 7.2.8. Medtronic
- 7.2.8.1. Company overview
- 7.2.8.2. Financial performance
- 7.2.8.3. Product benchmarking
- 7.2.8.4. Strategic initiatives
- 7.2.9. Jarvik Heart, Inc
- 7.2.9.1. Company overview
- 7.2.9.2. Financial performance
- 7.2.9.3. Product benchmarking
- 7.2.9.4. Strategic initiatives
- 7.2.10. SynCardia Systems, LLC
- 7.2.10.1. Company overview
- 7.2.10.2. Financial performance
- 7.2.10.3. Product benchmarking
- 7.2.10.4. Strategic initiatives